

Target Name	Adenosine A <sub>1</sub> receptor
Target TTD ID	TTDS00186

Target Species	Human
Chemical Type	Adenosine analogues
Mode of Action	Agonist
QSAR Model 1	$\log(A_1K_i) = -1.33(\pm 0.23) \cdot \log k' + 0.43(\pm 0.03) \cdot (\log k')^2 + 0.99(\pm 0.25)$ $N = 8 \quad S = 0.18 \quad R^2 = 0.99 \quad F = 128.21 \quad p < 0.0001$
Molecular Descriptor	<p>Access the following web-servers to compute molecular descriptors: <a href="#">MoDel</a> and <a href="#">e-dragon</a></p> <p>Log K': lipophilicity; N is the number of compounds included in the analysis, S is the root mean square error, R<sup>2</sup> is the square of the correlation coefficient, F relates the variance of the null hypothesis to the correlation variance, p is the probability that a random set of data would yield a higher F value, and terms are given ± their standard errors.</p>
Reference	Quantitative Structure Activity Relationships as Useful Tools for the Design of New Adenosine Receptor Ligands. 1. Agonist. <i>Current Medicinal Chemistry</i> , 2006, 13, 2253-2266

Target Species	Human
Chemical Type	Adenosine analogues
Mode of Action	Agonist
Activity	Adenosine derivatives with affinity for A <sub>1</sub> adenosine receptors

Type	
QSAR Model 1	$\log(K_i) = 23.886 - 8.143 \cdot (H8v) - 45.062 \cdot (REIG) - 10.686 \cdot (R2u^+) + 91.678 \cdot (R7u^+) - 11.937 \cdot (R5v) + 29425 \cdot (R1v^+)$ $N = 32 \quad S = 0.383 \quad R^2 = 0.773 \quad F = 14.188 \quad p < 10^{-5} \quad S_{CV-LOO} = 0.501 \quad q^2_{LOO} = 0.664$
Molecular Descriptor	<p>Access the following web-servers to compute molecular descriptors: <a href="#">MoDel</a> and <a href="#">e-dragon</a></p> <p>Topological: MSD, CIC1, VRA1, MPC09, piPC09, T(N..S)</p> <p>Galvez Topological Charges indexes: GGI2, GGI3, GGI8, GGI9, GGI10, JGI5</p> <p>Randic Molecular Profiles: DP01, SP03, SP04, SP07, SP12, SP13</p> <p>Geometrical: W3D, AGDD, DDI, ADDD, MAXDP, FDI</p> <p>WHIM: E3u, P2m, G3m, L2s, E2s, Gu</p> <p>GETAWAY: H8v, REIG, R2u+, R7u+, R5v, R1v+</p> <p>The REIG descriptor is defined as the first eigenvalue of the influence/distance matrix of the magnitude in question.</p>
Reference	Quantitative Structure Activity Relationships as Useful Tools for the Design of New Adenosine Receptor Ligands. 1. Agonist. <i>Current Medicinal Chemistry</i> , 2006, 13, 2253-2266

Target Species	Human
Chemical Type	Arylpiperazines
Mode of Action	Binder
QSAR Model 1	$\text{aff.} = 7.61 - 0.56 \text{ "Hbond acceptor"} + 0.18 \text{ "Rotlbonds"} + 1.15 \text{ "CHI-V-12_PC"}$ $\text{LOF}=0.21; \quad R^2=0.86; \quad F=70.85; \quad Q^2=0.82$
QSAR Model 2	$\text{aff.} = 7.78 + 1.33 \text{ "CHI-V-13_PC"} - 0.57 \text{ "Hbond acceptor"} + 0.19 \text{ "Rotlbonds"}$ $\text{LOF}=0.21; \quad R^2=0.85; \quad F=70.74; \quad Q^2=0.82$

<b>QSAR Model 3</b>	$\text{aff.} = 9.25 + 0.16 \text{ "Rotlbonds"} - 0.38 \text{ "Shadow-nu"} - 0.62 \text{ "Hbond acceptor"} + 1.47 \text{ "CHI-V-13\_PC"}$ $\text{LOF}=0.22; \quad R^2=0.88; \quad F=64.52; \quad Q^2=0.84$
<b>QSAR Model 4</b>	$\text{aff.} = 9.73 - 0.59 \text{ "Hbond acceptor"} + 0.21 \text{ "Rotlbonds"} + 1.78 \text{ "CHI-V-14\_PC"} - 0.09 \text{ "Shadow-Xlength"}$ $\text{LOF}=0.22; \quad R^2=0.88; \quad F=64.37; \quad Q^2=0.84$
<b>QSAR Model 5</b>	$\text{aff.} = 7.38 + 0.18 \text{ "Rotlbonds"} - 0.54 \text{ "Hbond acceptor"} + 1.01 \text{ "CHI-V-11\_PC"}$ $\text{LOF}=0.22; \quad R^2=0.85; \quad F=69.55; \quad Q^2=0.82$
<b>QSAR Model 6</b>	$\text{aff.} = 9.46 - 0.63 \text{ "Hbond acceptor"} + 1.71 \text{ "CHI-V-14\_PC"} + 0.17 \text{ "Rotlbonds"} - 0.41 \text{ "Shadow-nu"}$ $\text{LOF}=0.22; \quad R^2=0.88; \quad F=63.92; \quad Q^2=0.84$
<b>QSAR Model 7</b>	$\text{aff.} = 9.42 - 0.08 \text{ "Shadow-Xlength"} - 0.58 \text{ "Hbond acceptor"} + 1.52 \text{ "CHI-V-13\_PC"} + 0.19 \text{ "Rotlbonds"}$ $\text{LOF}=0.22; \quad R^2=0.88; \quad F=63.82; \quad Q^2=0.84$
<b>QSAR Model 8</b>	$\text{aff.} = 7.85 - 0.57 \text{ "Hbond acceptor"} + 1.52 \text{ "CHI-V-14\_PC"} + 0.20 \text{ "Rotlbonds"}$ $\text{LOF}=0.22; \quad R^2=0.85; \quad F=68.10; \quad Q^2=0.82$
<b>QSAR Model 9</b>	$\text{aff.} = 7.17 - 0.54 \text{ "Hbond acceptor"} + 0.18 \text{ "Rotlbonds"} + 0.91 \text{ "CHI-V-10\_PC"}$ $\text{LOF}=0.22; \quad R^2=0.85; \quad F=67.58; \quad Q^2=0.81$
<b>QSAR Model 10</b>	$\text{aff.} = 8.90 + 1.26 \text{ "CHI-V-12\_PC"} + 0.16 \text{ "Rotlbonds"} - 0.34 \text{ "Shadow-nu"} - 0.60 \text{ "Hbond acceptor"}$ $\text{LOF}=0.23; \quad R^2=0.88; \quad F=61.85; \quad Q^2=0.83$
<b>QSAR Model 11</b>	$-\log K_i = 7.61 - 0.56 (\pm 0.08) \text{ "Hbond acceptor"} + 0.18 (\pm 0.02) \text{ "Rotlbonds"} + 1.15 (\pm 0.13) \text{ "CHI-V-12\_PC"}$
<b>Molecular Descriptor</b>	<p>Access the following web-servers to compute molecular descriptors: <a href="#">MoDel</a> and <a href="#">e-dragon</a></p> <p>The term aff. represents <math>-\log K_i</math> where <math>K_i</math> is the affinity of compounds toward R1-AR, expressed in M concentrations. <math>R^2</math>, LOF, F, and <math>Q^2</math> are the coefficient of determination, the lack-of-fit value, the value from F test, and the cross-validated coefficient of determination, respectively.</p> <p>Descriptors, such as Rotlbonds (RB), Hbond acceptor (HBA), and a variable belonging to the CHI family. Both RB and CHI relate to the size of the molecules and CHI accounts for the connectivity of ligand structures.</p>

Reference	A Genetic-Function-Approximation-Based QSAR Model for the Affinity of Arylpiperazines toward $\alpha_1$ Adrenoceptors. <i>J. Chem. Inf. Model.</i> 2006, 46, 1466-1478
-----------	--

Target Species	Rat
Target Location	Brain
Chemical Type	8-substituted xanthenes
Mode of Action	Antagonist
QSAR Model 1	$pK_i(A_1) = 0.69 (\pm 0.16)\pi_8 - 1.43 (\pm 0.29)7CH_3 + 0.77 (\pm 0.18)\pi_1 + 4.46 (\pm 0.32)$ $n = 37; r = 0.78; s^2 = 0.68; F = 17.61.$
QSAR Model 2	$pK_i(A_1) = 0.64 (\pm 0.14)\pi_8 - 1.75 (\pm 0.27)7CH_3 + 1.49 (\pm 0.26)13DPR + 4.90 (\pm 0.24)$ $n = 37; r = 0.84; s^2 = 0.53; F = 25.42.$
QSAR Model 3	$p\bar{K}_i(A_1) = 0.65 (\pm 0.13)\pi_8 - 1.81 (\pm 0.25)7CH_3 + 1.43 (\pm 0.25)13DPR + 4.97 (\pm 0.23)$ $n = 36; r = 0.86; s^2 = 0.47; F = 29.34.$
QSAR Model 4	$pK_i(A_1) = 0.57 (\pm 0.11)\pi_8 - 2.06 (\pm 0.21)7CH_3 + 1.54 (\pm 0.20)13DPR - 59.21 (\pm 12.30)q_1 - 17.02 (\pm 4.56)$ $n = 37; r = 0.91; s^2 = 0.32; F = 37.66.$
Molecular Descriptor	<p>Access the following web-servers to compute molecular descriptors: <a href="#">MoDel</a> and <a href="#">e-dragon</a></p> <p><math>A_1</math> adenosine receptor binding affinity was measured by inhibition of [3H]-N6-phenylisopropyladenosine in rat brain membranes and by inhibition of N6-R-PIA-elicited inhibition of adenylate cyclase in rat fat cell membranes.</p> <p>In our MO calculations, we routinely examined: the net atomic charges; the energies of the highest occupied and lowest unoccupied molecular orbitals, the HOMO and LUMO, respectively; the dipole moments; and the donor and acceptor superdelocalizabilities.</p> <p>1) set of <math>\pi</math>-constants for the substituents: <math>\pi_1, \pi_3, \pi_7, \pi_8</math>, which describe the hydrophobicity of the</p>

	<p>substituents at the 1-, 3-, 7- and 8-positions, respectively;</p> <p>2) the set of <math>\sigma</math>-constants for the substituent <math>R^8</math>: <math>\sigma_m</math>, <math>\sigma_p</math>, <math>\sigma^*</math>, which describe the mesomeric and inductive effect of the <math>R^8</math>;</p> <p>3) the molecular refractivity of the substituent <math>R^8</math>, <math>MR^8</math>, which describes the volume of <math>R^8</math>;</p> <p>4) the set of quantum chemical indices discussed above; and</p> <p>5) the indicator variables 13DPR and 7CH, which account for the presence or absence of a certain group in a certain position. The indicator variable 13DPR has value 1 when propyl groups are attached to both <math>N^1</math> and <math>N^3</math> and value 0 when they are absent. The indicator variable 7CH<sub>3</sub> has value 1 when a methyl group is present at the 7-position and value 0 when a hydrogen is present. These indicator variables quantify the effect of a substituent on the biological activity that cannot be attributed to the physicochemical properties considered.</p>
<p><b>Reference</b></p>	<p>QSAR studies of S-substituted xanthenes as adenosine receptor antagonists. <i>Eur J Med Chem</i> (1994) 29,133-138</p>